These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9892381)

  • 1. Optimal hematocrit in patients on dialysis therapy.
    Nissenson AR
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S142-6. PubMed ID: 9892381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical efficacy of higher hematocrit levels in children with chronic renal insufficiency and those undergoing dialysis.
    Yorgin PD; Belson A; Al-Uzri AY; Alexander SR
    Semin Nephrol; 2001 Sep; 21(5):451-62. PubMed ID: 11559886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should the hematocrit (hemoglobin) be normalized in Pre-ESRD or dialysis patients? Yes!
    Besarab A; Aslam M
    Blood Purif; 2001; 19(2):168-74. PubMed ID: 11150804
    [No Abstract]   [Full Text] [Related]  

  • 4. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
    Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
    Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in anemia treatment with erythropoietin usage and patient outcomes.
    Collins AJ; Ma JZ; Xia A; Ebben J
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S133-41. PubMed ID: 9892380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
    Cotter DJ; Thamer M; Kimmel PL; Sadler JH
    Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
    Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
    Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In search of an optimal hematocrit level in dialysis patients: rehabilitation and quality-of-life implications.
    Paganini EP
    Am J Kidney Dis; 1994 Jul; 24(1 Suppl 1):S10-6; discussion S31-2. PubMed ID: 8023833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
    Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
    Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients.
    Volkova N; Arab L
    Am J Kidney Dis; 2006 Jan; 47(1):24-36. PubMed ID: 16377382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dialysis dose, membrane type, and anemia control.
    Young EW
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S157-60. PubMed ID: 9892384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalizing hematocrit in dialysis patients improves brain function.
    Pickett JL; Theberge DC; Brown WS; Schweitzer SU; Nissenson AR
    Am J Kidney Dis; 1999 Jun; 33(6):1122-30. PubMed ID: 10352201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).
    Benz RL; Pressman MR; Hovick ET; Peterson DD
    Am J Kidney Dis; 1999 Dec; 34(6):1089-95. PubMed ID: 10585319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
    Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
    JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
    Nissenson AR
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):25-31. PubMed ID: 2669083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure.
    Hayashi T; Suzuki A; Shoji T; Togawa M; Okada N; Tsubakihara Y; Imai E; Hori M
    Am J Kidney Dis; 2000 Feb; 35(2):250-6. PubMed ID: 10676724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.